Cramer’s Lighting Round: Arm is a buy


Stock Chart IconStock chart icon

hide content

Raymond James Financial’s year-to-date stock performance.

Raymond James Financial: “The thing is a horse. But it’s now valued more highly than JPMorgan. So, I’m going to have to say, it’s too late, we missed it, let’s find the next one.”

Stock Chart IconStock chart icon

hide content

Arm’s year-to-date stock performance.

Arm: “I like Arm very much [buy, buy, buy!].”

Stock Chart IconStock chart icon

hide content

Unity Software’s year-to-date stock performance.

Unity Software: “I would have told you to sell the stock. But, you know what, you can’t anymore. Why? Because Jim Whitehurst is now in charge, and Whitehurst is a winner. I am a buyer, I’ve changed my mind on the stock because he’s running it.”

Stock Chart IconStock chart icon

hide content

Comstock Resources’ year-to-date stock performance.

Comstock Resources: “I just think there’s so many other better there, I’m going to have to refer you to get to Coterra, CTRA, which is just a better situation.”

Stock Chart IconStock chart icon

hide content

Uber’s year-to-date stock performance.

Uber: “Uber I am very bullish on.”

Stock Chart IconStock chart icon

hide content

General Electric’s year-to-date stock performance.

General Electric: “…I’m not going to tell you to buy the stock. I can tell you to hold it, if it drops down, buy more. But I can’t tell you to sell it, it’s too good.”

Stock Chart IconStock chart icon

hide content

Teva’s year-to-date stock performance.

Teva: “I’ve been hard on Teva because I like Lilly, but the Teva situation is improving, and it’s ridiculously inexpensive. And they actually have some good scientists there. So, I’m not knocking Teva anymore. As a matter of fact, I’m going to go in on Teva.”

Stock Chart IconStock chart icon

hide content

Novo Nordisk’s year-to-date stock performance.

Novo Nordisk: “I think you should buy Lilly instead because Lilly’s going to have, in the next three months, some very good news on, I think, it’s anti-dementia drug.”

Stock Chart IconStock chart icon

hide content

SoundHound AI’s year-to-date stock performance.

SoundHound AI: “Some people say I killed SoundHound because at 9 I said I wouldn’t buy it. So, I didn’t mean to kill it, but at 6, I won’t buy it either.”

Jim Cramer’s Guide to Investing

Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.

Disclaimer The CNBC Investing Club Charitable Trust holds shares of Coterra and Eli Lilly.

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer TwitterFacebookInstagram

Questions, comments, suggestions for the “Mad Money” website? madcap@cnbc.com





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *